NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies

Alexander M. Spence, Mark Muzi, Jeanne M. Link, John M. Hoffman, Janet F. Eary, Kenneth A. Krohn

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Purpose: 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Procedures: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. Results: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. Conclusions: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalMolecular Imaging and Biology
Volume10
Issue number5
DOIs
StatePublished - Jun 10 2008

Keywords

  • 3′-[F-18]fluoro-3′-deoxythymidine
  • FLT
  • Fluorothymidine
  • Glioblastoma
  • Glioma
  • Positron emission tomography (PET)
  • Proliferation
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies'. Together they form a unique fingerprint.

  • Cite this